Can a Weight-Loss drug stop obesity before it starts? new trial aims to find out
NCT ID NCT06905626
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug Qsymia, combined with lifestyle coaching, can prevent obesity in 140 adolescents and young adults (ages 18-25) who are overweight (BMI 25-30) and have a family history of obesity. Participants will receive either Qsymia or a placebo, plus coaching on diet and exercise, for about one year. The main goal is to see if the drug helps maintain a healthy body mass index.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Qsymia (phentermine and topiramate extended-release)
- What this could lead to
- If successful, this could provide a proven way to prevent obesity in young people at high risk, reducing future health problems.
- What could go wrong
- This is a relatively small Phase 3 trial, and the drug may cause side effects. Results may not apply to all groups, and long-term safety is still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults